Clinical trial
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
NCT00076310 · M.D. Anderson Cancer Center, Other · Active, not recruiting
Key facts
| NCT number | NCT00076310 |
|---|---|
| Title | OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer |
| Official title | A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, OSI-774, Cisplatin |
| Enrollment | 50 |
| Start date | Jan 28, 2004 |
| Primary completion | Jun 30, 2026 |
| Completion | Jun 30, 2026 |
| First posted | Jan 21, 2004 |
| Last update posted | Jun 26, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: